Clinical and immunologic follow-up of patients who stop venom immunotherapy

M. U. Keating, A. Kagey-Sobotka, Robert G Hamilton, J. W. Yunginger

Research output: Contribution to journalArticle

Abstract

We prospectively studied 51 self-selected Hymenoptera sting-sensitive patients to determine (1) whether a minimal or optimal duration for venom immunotherapy (VIT) exists and (2) whether clinical or immunologic parameters exist that are predictive of clinical immunity after VIT was stopped. After 2 to 10 years of VIT, all patients had deliberate sting challenges (DSCs) from live insects. If DSCs were tolerated, patients voluntarily stopped VIT and returned annually for repeat venom skin tests (VSTs) and DSCs. In most patients, it was possible to monitor VST and venom-specific antibody (Ab) levels before and after VIT was stopped. One-year after VIT, VST and venom-specific IgE and IgG Ab level results were variable; 49 patients tolerated DSC, whereas two patients exhibited generalized reactions. These two patients had pre-VIT histories of grade IV field-sting reactions and had received VIT for 2 years and 4 years, respectively. The short-term (1 year) risk of recurrence of clinical allergy to stings after VIT was higher in patients who had experienced grade IV field-sting reactions before VIT versus patients experiencing grade I to III reactions before VIT ( 2 15, 13% versus 0 36, 0%) and higher in patients who had received VIT for less than 5 years versus patients who received VIT for 5 or more years (2/20, 10% versus 0/31, 0%). We suggest that VIT should be continued for 5 years in patients with pre-VIT field-sting reactions of grade IV severity. VST and venom-specific Ab results do not reliably predict the outcome of DSC or the subsequent clinical course in individual patients stopping VIT.

Original languageEnglish (US)
Pages (from-to)339-348
Number of pages10
JournalThe Journal of Allergy and Clinical Immunology
Volume88
Issue number3 PART 1
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Venoms
Immunotherapy
Bites and Stings
Skin Tests
Antibodies

Keywords

  • Hymenoptera
  • IgE antibodies
  • IgG antibodies
  • immunotherapy
  • venom

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Clinical and immunologic follow-up of patients who stop venom immunotherapy. / Keating, M. U.; Kagey-Sobotka, A.; Hamilton, Robert G; Yunginger, J. W.

In: The Journal of Allergy and Clinical Immunology, Vol. 88, No. 3 PART 1, 1991, p. 339-348.

Research output: Contribution to journalArticle

Keating, M. U. ; Kagey-Sobotka, A. ; Hamilton, Robert G ; Yunginger, J. W. / Clinical and immunologic follow-up of patients who stop venom immunotherapy. In: The Journal of Allergy and Clinical Immunology. 1991 ; Vol. 88, No. 3 PART 1. pp. 339-348.
@article{f23a929982a34dd08c10c12ebef8d1cf,
title = "Clinical and immunologic follow-up of patients who stop venom immunotherapy",
abstract = "We prospectively studied 51 self-selected Hymenoptera sting-sensitive patients to determine (1) whether a minimal or optimal duration for venom immunotherapy (VIT) exists and (2) whether clinical or immunologic parameters exist that are predictive of clinical immunity after VIT was stopped. After 2 to 10 years of VIT, all patients had deliberate sting challenges (DSCs) from live insects. If DSCs were tolerated, patients voluntarily stopped VIT and returned annually for repeat venom skin tests (VSTs) and DSCs. In most patients, it was possible to monitor VST and venom-specific antibody (Ab) levels before and after VIT was stopped. One-year after VIT, VST and venom-specific IgE and IgG Ab level results were variable; 49 patients tolerated DSC, whereas two patients exhibited generalized reactions. These two patients had pre-VIT histories of grade IV field-sting reactions and had received VIT for 2 years and 4 years, respectively. The short-term (1 year) risk of recurrence of clinical allergy to stings after VIT was higher in patients who had experienced grade IV field-sting reactions before VIT versus patients experiencing grade I to III reactions before VIT ( 2 15, 13{\%} versus 0 36, 0{\%}) and higher in patients who had received VIT for less than 5 years versus patients who received VIT for 5 or more years (2/20, 10{\%} versus 0/31, 0{\%}). We suggest that VIT should be continued for 5 years in patients with pre-VIT field-sting reactions of grade IV severity. VST and venom-specific Ab results do not reliably predict the outcome of DSC or the subsequent clinical course in individual patients stopping VIT.",
keywords = "Hymenoptera, IgE antibodies, IgG antibodies, immunotherapy, venom",
author = "Keating, {M. U.} and A. Kagey-Sobotka and Hamilton, {Robert G} and Yunginger, {J. W.}",
year = "1991",
doi = "10.1016/0091-6749(91)90095-6",
language = "English (US)",
volume = "88",
pages = "339--348",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3 PART 1",

}

TY - JOUR

T1 - Clinical and immunologic follow-up of patients who stop venom immunotherapy

AU - Keating, M. U.

AU - Kagey-Sobotka, A.

AU - Hamilton, Robert G

AU - Yunginger, J. W.

PY - 1991

Y1 - 1991

N2 - We prospectively studied 51 self-selected Hymenoptera sting-sensitive patients to determine (1) whether a minimal or optimal duration for venom immunotherapy (VIT) exists and (2) whether clinical or immunologic parameters exist that are predictive of clinical immunity after VIT was stopped. After 2 to 10 years of VIT, all patients had deliberate sting challenges (DSCs) from live insects. If DSCs were tolerated, patients voluntarily stopped VIT and returned annually for repeat venom skin tests (VSTs) and DSCs. In most patients, it was possible to monitor VST and venom-specific antibody (Ab) levels before and after VIT was stopped. One-year after VIT, VST and venom-specific IgE and IgG Ab level results were variable; 49 patients tolerated DSC, whereas two patients exhibited generalized reactions. These two patients had pre-VIT histories of grade IV field-sting reactions and had received VIT for 2 years and 4 years, respectively. The short-term (1 year) risk of recurrence of clinical allergy to stings after VIT was higher in patients who had experienced grade IV field-sting reactions before VIT versus patients experiencing grade I to III reactions before VIT ( 2 15, 13% versus 0 36, 0%) and higher in patients who had received VIT for less than 5 years versus patients who received VIT for 5 or more years (2/20, 10% versus 0/31, 0%). We suggest that VIT should be continued for 5 years in patients with pre-VIT field-sting reactions of grade IV severity. VST and venom-specific Ab results do not reliably predict the outcome of DSC or the subsequent clinical course in individual patients stopping VIT.

AB - We prospectively studied 51 self-selected Hymenoptera sting-sensitive patients to determine (1) whether a minimal or optimal duration for venom immunotherapy (VIT) exists and (2) whether clinical or immunologic parameters exist that are predictive of clinical immunity after VIT was stopped. After 2 to 10 years of VIT, all patients had deliberate sting challenges (DSCs) from live insects. If DSCs were tolerated, patients voluntarily stopped VIT and returned annually for repeat venom skin tests (VSTs) and DSCs. In most patients, it was possible to monitor VST and venom-specific antibody (Ab) levels before and after VIT was stopped. One-year after VIT, VST and venom-specific IgE and IgG Ab level results were variable; 49 patients tolerated DSC, whereas two patients exhibited generalized reactions. These two patients had pre-VIT histories of grade IV field-sting reactions and had received VIT for 2 years and 4 years, respectively. The short-term (1 year) risk of recurrence of clinical allergy to stings after VIT was higher in patients who had experienced grade IV field-sting reactions before VIT versus patients experiencing grade I to III reactions before VIT ( 2 15, 13% versus 0 36, 0%) and higher in patients who had received VIT for less than 5 years versus patients who received VIT for 5 or more years (2/20, 10% versus 0/31, 0%). We suggest that VIT should be continued for 5 years in patients with pre-VIT field-sting reactions of grade IV severity. VST and venom-specific Ab results do not reliably predict the outcome of DSC or the subsequent clinical course in individual patients stopping VIT.

KW - Hymenoptera

KW - IgE antibodies

KW - IgG antibodies

KW - immunotherapy

KW - venom

UR - http://www.scopus.com/inward/record.url?scp=0026010063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026010063&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(91)90095-6

DO - 10.1016/0091-6749(91)90095-6

M3 - Article

C2 - 1890261

AN - SCOPUS:0026010063

VL - 88

SP - 339

EP - 348

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3 PART 1

ER -